• 제목/요약/키워드: hematopoietic stem cells

검색결과 165건 처리시간 0.029초

Dendritic Cell (DC) Vaccine in Mouse Lung Cancer Minimal Residual Model: Comparison of Monocyte-derived DC vs. Hematopoietic Stem Cell Derived-DC

  • Baek, Soyoung;Lee, Seog Jae;Kim, Myoung Joo;Lee, Hyunah
    • IMMUNE NETWORK
    • /
    • 제12권6호
    • /
    • pp.269-276
    • /
    • 2012
  • The anti-tumor effect of monocyte-derived DC (MoDC) vaccine was studied in lung cancer model with feasible but weak Ag-specific immune response and incomplete blocking of tumor growth. To overcome this limitation, the hematopoietic stem cell-derived DC (SDC) was cultured and the anti-tumor effect of MoDC & SDC was compared in mouse lung cancer minimal residual model (MRD). Therapeutic DCs were cultured from either $CD34^+$ hematopoietic stem cells with GM-CSF, SCF and IL-4 for 14 days (SDC) or monocytes with GM-CSF and IL-4 for 7 days (MoDC). DCs were injected twice by one week interval into the peritoneum of mice that are inoculated with Lewis Lung Carcinoma cells (LLC) one day before the DC injection. Anti-tumor responses and the immune modulation were observed 3 weeks after the final DC injection. CD11c expression, IL-12 and TGF-${\beta}$ secretion were higher in SDC but CCR7 expression, IFN-${\gamma}$ and IL-10 secretion were higher in MoDC. The proportion of $CD11c^+CD8a^+$ cells was similar in both DC cultures. Although both DC reduced the tumor burden, histological anti-tumor effect and the frequencies of IFN-${\gamma}$ secreting $CD8^+$ T cells were higher in SDC treated group than in MoDC. Conclusively, although both MoDC and SDC can induce the anti-tumor immunity, SDC may be better module as anti-tumor vaccine than MoDC in mouse lung cancer.

Agonist (P1) Antibody Converts Stem Cells into Migrating Beta-Like Cells in Pancreatic Islets

  • Eun Ji Lee;Seung-Ho Baek;Chi Hun Song;Yong Hwan Choi;Kyung Ho Han
    • Journal of Microbiology and Biotechnology
    • /
    • 제32권12호
    • /
    • pp.1615-1621
    • /
    • 2022
  • Tissue regeneration is the ultimate treatment for many degenerative diseases, however, repair and regeneration of damaged organs or tissues remains a challenge. Previously, we showed that B1 Ab and H3 Ab induce stem cells to differentiate into microglia and brown adipocyte-like cells, while trafficking to the brain and heart, respectively. Here, we present data showing that another selected agonist antibody, P1 antibody, induces the migration of cells to the pancreatic islets and differentiates human stem cells into beta-like cells. Interestingly, our results suggest the purified P1 Ab induces beta-like cells from fresh, human CD34+ hematopoietic stem cells and mouse bone marrow. In addition, stem cells with P1 Ab bound to expressed periostin (POSTN), an extracellular matrix protein that regulates tissue remodeling, selectively migrate to mouse pancreatic islets. Thus, these results confirm that our in vivo selection system can be used to identify antibodies from our library which are capable of inducing stem cell differentiation and cell migration to select tissues for the purpose of regenerating and remodeling damaged organ systems.

Biological Response Modifiers Influence Structure Function Relationship of Hematopoietic Stem and Stromal Cells in a Mouse Model of Leukemia

  • Basu, Kaustuv;Mukherjee, Joydeep;Law, Sujata;Chaudhuri, Samaresh
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제13권6호
    • /
    • pp.2935-2941
    • /
    • 2012
  • Biological response modifiers (BRMs) can alter interactions between the immune system and cancer cells to boost, direct, or restore the body's ability to fight disease. Mice with ethylnitrosourea- (ENU) induced leukemia were here used to monitor the therapeutic efficacy of lipopolysaccaride (LPS), Bacillus Calmette Guerin (BCG) and sheep erythrocytes (SRBC). Flow cytometry based CD34+ positivity analysis, clonogenicity, proliferation and ultrastructure studies using scanning electron microscopy (SEM) of stem cells in ENU induced animals with and without BRMs treatment were performed. BRMs improved the stem-stromal relationship structurally and functionally and might have potential for use as an adjunct in human stem cell therapy.

골수기질세포에서 방사선 반응 유전자로서의 Plasminogen Activator Inhibitor-1 (Plasminogen Activator Inhibitor-1 as a Radiation-Responsive Gene in Bone Marrow Stromal Cells)

  • 송지연;권형주;박찬규;조덕연;이영희
    • 한국발생생물학회지:발생과생식
    • /
    • 제9권1호
    • /
    • pp.43-48
    • /
    • 2005
  • 조혈세포의 주요 서식지가 되는 골수기질세포는 줄기세포의 운영을 결정하는 다양한 인자들을 제공한다. 방사선 요법은 항암치료법으로 널리 활용되고 있으나, 조혈세포의 파괴로 인한 부작용이 심각한 문제로서 조혈세포에 의한 혈액 세포가 빠른 시간 내에 회복되는 것이 필수적이다. 본 연구에서는 방사선을 조사했을 때의 줄기세포 서식지를 구성하는 세포인 골수기질세포에서 발현되는 유전자를 탐색하여 그 기능과 조절 및 혈액 형성을 이해하는 기초를 마련하고자 하였다. 방법론적으로는 polymerase chain reaction(PCR) 및 agarose 전기영동 방법을 활용한 differential display를 활용하였으며, 결과로서 여러 후보 유전자가 선별되었으나, plasminogen activator inhibitor-1(PAI-1) 유전자만이 감마선에 의해 유도됨이 반복 확인되었다. PAI-1 유전자 유도의 의미는 향후에 더 연구해야 할 것이다.

  • PDF

Exploring the Molecular and Developmental Dynamics of Endothelial Cell Differentiation

  • Yu Jung Shin;Jung Hyun Lee
    • International Journal of Stem Cells
    • /
    • 제17권1호
    • /
    • pp.15-29
    • /
    • 2024
  • The development and differentiation of endothelial cells (ECs) are fundamental processes with significant implications for both health and disease. ECs, which are found in all organs and blood vessels, play a crucial role in facilitating nutrient and waste exchange and maintaining proper vessel function. Understanding the intricate signaling pathways involved in EC development holds great promise for enhancing vascularization, tissue engineering, and vascular regeneration. Hematopoietic stem cells originating from hemogenic ECs, give rise to diverse immune cell populations, and the interaction between ECs and immune cells is vital for maintaining vascular integrity and regulating immune responses. Dysregulation of vascular development pathways can lead to various diseases, including cancer, where tumor-specific ECs promote tumor growth through angiogenesis. Recent advancements in single-cell genomics and in vivo genetic labeling have shed light on EC development, plasticity, and heterogeneity, uncovering tissue-specific gene expression and crucial signaling pathways. This review explores the potential of ECs in various applications, presenting novel opportunities for advancing vascular medicine and treatment strategies.

제대혈액에서 골조직 특이세포로의 분화 (Differentiation of Osteoblast Progenitor Cells from Human Umbilical Cord Blood)

  • 홍승진;이은아;채규태;한훈
    • IMMUNE NETWORK
    • /
    • 제2권3호
    • /
    • pp.166-174
    • /
    • 2002
  • Background: Human umbilical cord bloods, which could be taken during the delivery are utilized as a source of hematopoietic stem cells. Also in cord blood, there are several kinds of stem cells such as endothelial and mesenchymal stem cells. Methods: We isolated the mesenchymal stem cells from human umbilical cord bloods and confirmed the differentiation of these cells into osteoblast progenitor cells. The mesenchymal stem cells derived from umbilical cord blood have the ability to differentiate into specific tissue cells, which is one of characteristics of stem cells. These cells were originated from the multipolar shaped cells out of adherent cells of the umbilical cord blood mononuclear cell culture. Results: The mesenchymal stem cells expressed cell surface antigen CD13, CD90, CD102, CD105, ${\alpha}$-smooth muscle actin and cytoplasmic antigen vimentine. Having cultrued these cells in bone formation media, we observed the formation of extracellular matrix and the expression of alkaline phosphatase and of mRNA of cbfa-1, ostoecalcin and type I collagen. Conclusion: From these results we concluded that the cells isolated from the umbilical cord blood were mesenchymal stem cells, which we could differentiate into osteoblast when cultured in bone formation media. In short, it is suggested that these cells could be used as a new source of stem cells, which has the probability to alternate the embryonic stem cells.

Characterization of the KG1a Cell Line for Use in a Cell Migration Based Screening Assay

  • Bernhard O. Palsson;Karl francis;Lee, Gyun-Min
    • Biotechnology and Bioprocess Engineering:BBE
    • /
    • 제7권3호
    • /
    • pp.178-184
    • /
    • 2002
  • High-throughput screening has become a popular method used to identify new “leads”for potentially therapeutic compounds. Further screening of these lead compounds is typically done with secondary assays which may utilize living, functioning cells as screening tools. A problem (or benefit) with these cell-based assays is that living cells are very sensitive to their environment. We have been interested in the process of stem cell migration and how it relates to the cellular therapy of bone marrow transplantation. In this study we describe a secondary, cell-based assay for screening the effects of various in-vitro conditions on Immature Hematopoietic Cell (IHC) migration. Our results have revealed many subtle factors, such as the cell's adhesive characteristics, or the effect of a culture's growth phase, that need to be accounted for in a screening protocol. Finally, we show that exponentially glowing KG1a cells (a human IHC cell line) were 10 times more motile than those in the lag or stationary phases. These data strongly suggest that KG1a cells secrete a chemokinetic factor during the exponential growth phase of a culture.

Humanized mouse model for vaccine evaluation: an overview

  • Shivani Kaushik;Lata Kumari;Rakesh Kumar Deepak
    • Clinical and Experimental Vaccine Research
    • /
    • 제13권1호
    • /
    • pp.10-20
    • /
    • 2024
  • Animal models are essential in medical research for testing drugs and vaccines. These models differ from humans in various respects, so their results are not directly translatable in humans. To address this issue, humanized mice engrafted with functional human cells or tissue can be helpful. We propose using humanized mice that support the engraftment of human hematopoietic stem cells (HSCs) without irradiation to evaluate vaccines that influence patient immunity. For infectious diseases, several types of antigens and adjuvants have been developed and evaluated for vaccination. Peptide vaccines are generally used for their capability to fight cancer and infectious diseases. Evaluation of adjuvants is necessary as they induce inflammation, which is effective for an enhanced immune response but causes adverse effects in some individuals. A trial can be done on humanized mice to check the immunogenicity of a particular adjuvant and peptide combination. Messenger RNA has also emerged as a potential vaccine against viruses. These vaccines need to be tested with human immune cells because they work by producing a particular peptide of the pathogen. Humanized mice with human HSCs that can produce both myeloid and lymphoid cells show a similar immune response that these vaccines will produce in a patient.